← All trials
NCT04725682
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 5, 2021
- Primary completion
- May 14, 2021
- Completion date
- Jun 17, 2021
- First posted
- Jan 27, 2021
- Last posted
- Jun 30, 2021
- Enrollment
- 68
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Food and Drug AdministrationLead sponsor
- BioPharma ServicesOverall official - principal investigator
- BioPharma ServicesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.